Stock Track | Alnylam Pharmaceuticals Plummets 5.03% Intraday on Q4 Revenue Miss and Weak 2026 Guidance

Stock Track02-12

Alnylam Pharmaceuticals (ALNY) shares plummeted 5.03% during intraday trading on Thursday, following the release of the company's fourth-quarter financial results.

The biopharmaceutical company reported Q4 2025 net product revenue of $1.10 billion, which missed analyst expectations of $1.17 billion. While the company posted strong year-over-year growth and beat earnings estimates, the revenue shortfall disappointed investors.

Adding to the negative sentiment, Alnylam issued 2026 net product revenue guidance in the range of $4.9 billion to $5.3 billion, which fell below the analyst consensus estimate of $5.64 billion. The combination of the Q4 revenue miss and weaker-than-expected forward guidance triggered the sharp decline in the company's stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161353209?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161353209","market":"nz","top_or_hot":-1,"title":"Stock Track | Alnylam Pharmaceuticals Plummets 5.03% Intraday on Q4 Revenue Miss and Weak 2026 Guidance","media":"Stock Track","content":"<p>Alnylam Pharmaceuticals (ALNY) shares plummeted 5.03% during intraday trading on Thursday, following the release of the company's fourth-quarter financial results.</p><p>The biopharmaceutical company reported Q4 2025 net product revenue of $1.10 billion, which missed analyst expectations of $1.17 billion. While the company posted strong year-over-year growth and beat earnings estimates, the revenue shortfall disappointed investors.</p><p>Adding to the negative sentiment, Alnylam issued 2026 net product revenue guidance in the range of $4.9 billion to $5.3 billion, which fell below the analyst consensus estimate of $5.64 billion. The combination of the Q4 revenue miss and weaker-than-expected forward guidance triggered the sharp decline in the company's stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Alnylam Pharmaceuticals Plummets 5.03% Intraday on Q4 Revenue Miss and Weak 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Alnylam Pharmaceuticals Plummets 5.03% Intraday on Q4 Revenue Miss and Weak 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-12 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alnylam Pharmaceuticals (ALNY) shares plummeted 5.03% during intraday trading on Thursday, following the release of the company's fourth-quarter financial results.</p><p>The biopharmaceutical company reported Q4 2025 net product revenue of $1.10 billion, which missed analyst expectations of $1.17 billion. While the company posted strong year-over-year growth and beat earnings estimates, the revenue shortfall disappointed investors.</p><p>Adding to the negative sentiment, Alnylam issued 2026 net product revenue guidance in the range of $4.9 billion to $5.3 billion, which fell below the analyst consensus estimate of $5.64 billion. The combination of the Q4 revenue miss and weaker-than-expected forward guidance triggered the sharp decline in the company's stock price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALNY","symbol_name":"阿尔尼拉姆制药公司","start_time":0,"source_url":"","article_id":"1161353209","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161353209","pubTimestamp":1770907208,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Alnylam Pharmaceuticals (ALNY) shares plummeted 5.03% during intraday trading on Thursday, following the release of the company's fourth-quarter financial results.The biopharmaceutical company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALNY":"阿尔尼拉姆制药公司"},"translate_title":"个股赛道|Alnylam Pharmaceuticals盘中暴跌5.03%，因Q4营收未达预期且2026年指引疲弱","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1},"content_text":"Alnylam Pharmaceuticals (ALNY) shares plummeted 5.03% during intraday trading on Thursday, following the release of the company's fourth-quarter financial results.The biopharmaceutical company reported Q4 2025 net product revenue of $1.10 billion, which missed analyst expectations of $1.17 billion. While the company posted strong year-over-year growth and beat earnings estimates, the revenue shortfall disappointed investors.Adding to the negative sentiment, Alnylam issued 2026 net product revenue guidance in the range of $4.9 billion to $5.3 billion, which fell below the analyst consensus estimate of $5.64 billion. The combination of the Q4 revenue miss and weaker-than-expected forward guidance triggered the sharp decline in the company's stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161353209","isCrawlerRequest":true}